Alipov et al. compared the expression of the ETS1 proto-oncogene in latent PC, benign prostatic hyperplasia, normal prostatic tissues, and clinical PC [60], reporting negative expression in benign tissues and higher levels in clinical PC than in latent PC. Here, ETS1 is linked to benign prostatic hyperplasia.